These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15290343)

  • 21. Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
    Grosso H; Mouradian MM
    Pharmacol Ther; 2012 Mar; 133(3):392-410. PubMed ID: 22212614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
    Iannaccone M; Titta F; Serretiello E; De Vivo G; Martin A; Gentile V
    Recent Pat CNS Drug Discov; 2013 Dec; 8(3):235-42. PubMed ID: 24286449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
    Rockenstein E; Crews L; Masliah E
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1093-102. PubMed ID: 17869376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
    J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation and characterization of brain-specific transglutaminases from rat.
    Kwak SJ; Kim SY; Kim YS; Song KY; Kim IG; Park SC
    Exp Mol Med; 1998 Dec; 30(4):177-85. PubMed ID: 9894146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
    De Vivo G; Gentile V
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):370-5. PubMed ID: 18991665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting JNK3 for the treatment of neurodegenerative disorders.
    Resnick L; Fennell M
    Drug Discov Today; 2004 Nov; 9(21):932-9. PubMed ID: 15501728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases.
    Bailey CD; Graham RM; Nanda N; Davies PJ; Johnson GV
    Mol Cell Neurosci; 2004 Mar; 25(3):493-503. PubMed ID: 15033177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical mechanisms for a possible involvement of the transglutaminase activity in the pathogenesis of the polyglutamine diseases: minireview article.
    Pepe I; Occhino E; Cella G; Luongo A; Guardascione F; Gentile V
    Amino Acids; 2004 Jul; 26(4):431-4. PubMed ID: 15290350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM; Fischer DF; Ovaa H; Scheper W
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transglutaminase 2 induces nitric oxide synthesis in BV-2 microglia.
    Park KC; Chung KC; Kim YS; Lee J; Joh TH; Kim SY
    Biochem Biophys Res Commun; 2004 Oct; 323(3):1055-62. PubMed ID: 15381106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
    Iannaccone M; Titta F; Serretiello E; Monfregola M; Gentile V
    Recent Pat CNS Drug Discov; 2014; 9(2):76-84. PubMed ID: 25386917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking.
    Konno T; Morii T; Hirata A; Sato S; Oiki S; Ikura K
    Biochemistry; 2005 Feb; 44(6):2072-9. PubMed ID: 15697232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transglutaminase activity changes during the hypersensitive reaction, a typical defense response of tobacco NN plants to TMV.
    Del Duca S; Betti L; Trebbi G; Serafini-Fracassini D; Torrigiani P
    Physiol Plant; 2007 Oct; 131(2):241-50. PubMed ID: 18251895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Possible physiopathological roles of the transglutaminase activity in the etiopathogenesis of human neurodegenerative diseases.
    Titta F; Iannaccone M; Martin A; Gentile V
    Recent Pat CNS Drug Discov; 2014; 9(2):101-9. PubMed ID: 24924102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
    Sas K; Robotka H; Toldi J; Vécsei L
    J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases.
    Walker DG; Lue LF
    J Neurosci Res; 2005 Aug; 81(3):412-25. PubMed ID: 15957156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transglutaminases as targets for pharmacological inhibition.
    Wodzinska JM
    Mini Rev Med Chem; 2005 Mar; 5(3):279-92. PubMed ID: 15777262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
    De Vivo G; Di Lorenzo R; Ricotta M; Gentile V
    Curr Med Chem; 2009; 16(36):4767-73. PubMed ID: 19929789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leishmania species: evidence for transglutaminase activity and its role in parasite proliferation.
    Brobey RK; Soong L
    Exp Parasitol; 2006 Oct; 114(2):94-102. PubMed ID: 16620812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.